SELE

Summary

SELE (selectin E, HGNC:10718) is a protein-coding gene on chromosome 1q24.2, encoding E-selectin (P16581). Cell-surface glycoprotein having a role in immunoadhesion.

The protein encoded by this gene is found in cytokine-stimulated endothelial cells and is thought to be responsible for the accumulation of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. It exhibits structural features such as the presence of lectin- and EGF-like domains followed by short consensus repeat (SCR) domains that contain 6 conserved cysteine residues. These proteins are part of the selectin family of cell adhesion molecules. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.

Source: NCBI Gene 6401 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 92 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10718
Approved symbol	SELE
Name	selectin E
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	ESEL, CD62E
Ensembl gene	ENSG00000007908
Ensembl biotype	protein_coding
OMIM	131210
Entrez	6401

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 retained_intron

ENST00000333360, ENST00000367774, ENST00000367775, ENST00000367776, ENST00000367777, ENST00000461085, ENST00000609271

RefSeq mRNA: 1 — MANE Select: NM_000450 NM_000450

CCDS: CCDS1283

Canonical transcript exons

ENST00000333360 — 14 exons

Exon	Start	End
ENSE00000451012	169729488	169729673
ENSE00000451027	169727739	169727927
ENSE00000451043	169726699	169726806
ENSE00000789637	169725907	169725928
ENSE00000789639	169727349	169727525
ENSE00000789641	169728058	169728246
ENSE00000789642	169729186	169729374
ENSE00000789644	169730432	169730617
ENSE00000789645	169731835	169731942
ENSE00000814463	169732615	169732998
ENSE00000814464	169725729	169725801
ENSE00001367867	169733576	169733660
ENSE00001950222	169733971	169734079
ENSE00003845714	169722640	169724509

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 99.08.

FANTOM5 (CAGE): breadth broad, TPM avg 7.3226 / max 537.1415, expressed in 245 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15861	7.3126	245
15862	0.0101	3

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	99.08	gold quality
left uterine tube	UBERON:0001303	91.18	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.18	gold quality
seminal vesicle	UBERON:0000998	86.50	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.93	gold quality
trachea	UBERON:0003126	85.01	gold quality
mucosa of stomach	UBERON:0001199	84.71	gold quality
cartilage tissue	UBERON:0002418	83.99	gold quality
mucosa of urinary bladder	UBERON:0001259	82.68	gold quality
gall bladder	UBERON:0002110	82.00	gold quality
saphenous vein	UBERON:0007318	81.15	gold quality
right lobe of thyroid gland	UBERON:0001119	80.22	gold quality
mucosa of paranasal sinus	UBERON:0005030	78.60	gold quality
omental fat pad	UBERON:0010414	76.96	gold quality
peritoneum	UBERON:0002358	76.86	gold quality
left lobe of thyroid gland	UBERON:0001120	76.82	gold quality
thyroid gland	UBERON:0002046	76.52	gold quality
parietal pleura	UBERON:0002400	76.44	gold quality
vermiform appendix	UBERON:0001154	76.01	gold quality
superficial temporal artery	UBERON:0001614	75.76	gold quality
pleura	UBERON:0000977	75.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	75.36	gold quality
adipose tissue of abdominal region	UBERON:0007808	74.98	gold quality
prostate gland	UBERON:0002367	74.60	gold quality
right lobe of liver	UBERON:0001114	73.75	gold quality
smooth muscle tissue	UBERON:0001135	73.71	gold quality
periodontal ligament	UBERON:0008266	72.97	gold quality
penis	UBERON:0000989	72.94	gold quality
colonic epithelium	UBERON:0000397	72.07	gold quality
visceral pleura	UBERON:0002401	71.76	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10137	yes	5426.25
E-MTAB-9841	yes	4064.98
E-GEOD-135922	yes	34.18
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, AR, ATF2, ATF3, ATF7, CCL3, CUX1, E2F1, EGR1, ETS1, GDF2, GLI2, HMGA1, HMGA2, HOXA9, IL1B, JUN, KLF2, KLF4, NCOA1, NFKB1, NFKB, NFKBIE, NRG1, POU2F1, PPARA, REL, RELA, SIRT1, STAT6, TNF, ZBTB7A, ZHX2

miRNA regulators (miRDB)

96 targeting SELE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-204-5P	99.79	71.62	2439

Literature-anchored findings (GeneRIF, showing 40)

• circadian variations in healthy adults and in subjects with type II diabetes; possible role in increased vascular wall uptake of lipoproteins in diabetic subjects (PMID:11697721)
• The e-selectin C allele was more common in systemic lupus erythematosus than in controls. E-selectin may be a susceptibility gene to systemic lupus erythematosus in these populations. (PMID:11764211)
• Premature labor is associated with up-regulation of adhesion molecules in the lower uterine segment (PMID:11776680)
• activation of expression by HIV-1 tat protein via NF-kappa B-dependent mechanism (PMID:11827962)
• two SNPs in the E-selectin gene and six SNPs in the L-selectin gene were significantly associated with IgAN in Japanese patients (PMID:11828340)
• significant increase in plasma levels between day 1 and day 5 of G-CSF-induced stem cell mobilization; possible effect on leukocyte-endothelial cell interactions (PMID:11847011)
• role of phosphoserine-type di-leucine motif in E-selectin internalization (PMID:11859093)
• E-selectin and vWF were not correlated with percent body fat, but were negatively correlated with M (r= -0.65 and -0.46, both P<0.001) and positively correlated with CRP (r=0.46, and 0.33, both P<0.05). (PMID:11882337)
• Human mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1, E-selectin for adhesive interactions with human vascular endothelium under flow conditions (PMID:11929779)
• relation between glycemic control, hyperinsulinism and plasma concentration in patints with glucose intolerance or NIDDM (PMID:11935152)
• results showed that sP-selectin and sE-selectin levels were higher in patients with lung cancer compared to normal donors; increased levels of sP-selectin and sE-selectin were associated with squamous lung cancer at late stages but not adenocarcinoma (PMID:11936588)
• inhibition of cytokine induction of promoter by 17beta-estradiol (PMID:11948013)
• Eosinophil interaction with endothelial P-selectin is far more important than interaction with E-selectin for recruitment into the inflamed skin of patients with atopic dermatitis. (PMID:11981814)
• E-selectin blood levels are no different in non-Hodgkin’s lymphoma patients and controls (PMID:12011765)
• X-irradiation 2-5 h before stimulation decreased the characteristic transient expression of E-selectin after TNFalpha stimulation. (PMID:12020443)
• the preferential expression of selectin E on the endothelium of femoral and iliac arteries in thromboangiitis obliterans (PMID:12086338)
• CD62L on human cultured T lymphoblasts is one of several glycoproteins that interacts directly with E-selectin and contributes to rolling under flow. (PMID:12165498)
• E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion molecule-1 (VCAM-1) were measured in serum from hypertensive patients with LV hypertrophy (PMID:12172318)
• Downregulation of e-selectin is associated with nodal metastasis in breast cancer (PMID:12172576)
• circulating soluble selectin E in acute myeloid leukemia is correlated with peripheral blast cell counts, extramedullaary infiltration, relapse and mortality (PMID:12186696)
• Conjunctival biopsies excised from patients following cataract surgery did not show that endothelial E-selectin might play a role in the surgery-induced up-regulation of leukocyte rolling. (PMID:12200386)
• enhanced expression of E-selectin may contribute to the development of diabetic maculopathy in type 2 diabetes (PMID:12388172)
• A serine to arginine (S128R) polymorphism in E-selectin extends the range of lymphocytes recruited by E-selectin, which may provide a mechanistic link between this polymorphism and vascular inflammatory disease. (PMID:12421968)
• interacts with fuco-oligosaccharides of the blood group family (PMID:12499405)
• is a potent mediator of human dermal microvascular endothelial cell (HMVEC) chemotaxis, which is predominantly mediated through the Src and the phosphatidylinositiol 3-kinase (PI3K) pathways (PMID:12522014)
• The E-selectin Ser128Arg polymorphism can functionally alter leukocyte-endothelial interactions as well as biochemical and biological consequences, which may account for the pathogenesis of myocardial infarction. (PMID:12649084)
• Endothelial cells have increased expression of VCAM-1, E-selectin, and ICAM-1 when exposed to sickle blood cells. (PMID:12673844)
• Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. (PMID:12698264)
• interacts with Helicobacter pylori isolates from patients with chronic gastritis, duodenal ulcer and gastric cancer (PMID:12738381)
• Extravasated and oxidized LDL in xanthoma adds to foam cell recruitment by activating tyrosine kinase and inducing adhesion of monocytes to dermal microvascular endothelial cells through VCAM-1 and E-selectin. (PMID:12788528)
• High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma (PMID:12792758)
• The adhesion of E-selectin expressing CHO cells to the coated mucins was analyzed in a flow system revealing that the MUC1 mucin adhered better than the CD43 mucin (PMID:12820726)
• central obese subjects with concomitant higher levels of selectin E and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease (PMID:12898464)
• Blood levels do not differ in normal and coronary artery disease patients. (PMID:12940514)
• Localization of E-selectin in lipid rafts is necessary for its association with, and activation of, phospholipase C gamma. (PMID:12960351)
• Adrenomedullin and ACTH induce cell surface expression of adhesion molecules E-selectin, VCAM-1, and ICAM-1 on human umbilical vein endothelial cells. (PMID:14534081)
• E-selectin has a role in promoting growth inhibition and apoptosis of human and murine hematopoietic progenitor cells independent of PSGL-1 (PMID:14592840)
• E-selectin and its ligand-sLeX are closely correlated with the metastasis of hepatocellular carcinoma (PMID:14607629)
• minor trauma to skin may induce expression of E-selectin, ICAM-1 and IL-8 (PMID:14714557)
• Coexpression of E-selectin with ICAM-1 and CCL17 on blood vessels in noninflamed skin provides the basis for a model of cutaneous immunosurveillance system active in the absence of pathologic inflammation. (PMID:14734737)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	selp	ENSDARG00000042138
mus_musculus	Sele	ENSMUSG00000026582
rattus_norvegicus	Sele	ENSRNOG00000002723

Paralogs (39): CFH (ENSG00000000971), C8B (ENSG00000021852), C6 (ENSG00000039537), SEZ6 (ENSG00000063015), CFHR2 (ENSG00000080910), APOH (ENSG00000091583), SEZ6L (ENSG00000100095), SUSD6 (ENSG00000100647), SRPX (ENSG00000101955), SRPX2 (ENSG00000102359), C7 (ENSG00000112936), C9 (ENSG00000113600), PAPPA2 (ENSG00000116183), CFHR3 (ENSG00000116785), CR2 (ENSG00000117322), CD46 (ENSG00000117335), CSMD2 (ENSG00000121904), C4BPA (ENSG00000123838), C4BPB (ENSG00000123843), CFHR4 (ENSG00000134365), CFHR5 (ENSG00000134389), F13B (ENSG00000143278), SUSD4 (ENSG00000143502), C8A (ENSG00000157131), SUSD3 (ENSG00000157303), CSMD3 (ENSG00000164796), SVEP1 (ENSG00000165124), C2 (ENSG00000166278), SELP (ENSG00000174175), SEZ6L2 (ENSG00000174938), PRF1 (ENSG00000180644), PAPPA (ENSG00000182752), CSMD1 (ENSG00000183117), SELL (ENSG00000188404), CD55 (ENSG00000196352), CR1L (ENSG00000197721), CR1 (ENSG00000203710), CFB (ENSG00000243649), CFHR1 (ENSG00000244414)

Protein

Protein identifiers

E-selectin — P16581 (reviewed: P16581)

Alternative names: CD62 antigen-like family member E, Endothelial leukocyte adhesion molecule 1, Leukocyte-endothelial cell adhesion molecule 2

All UniProt accessions (6): P16581, Q5TI72, Q5TI73, Q5TI74, Q5TI75, V9GYI4

UniProt curated annotations — full annotation on UniProt →

Function. Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis.

Subunit / interactions. Interacts with SELPLG/PSGL1 and PODXL2 through the sialyl Lewis X epitope. SELPLG sulfation appears not to be required for this interaction.

Subcellular location. Cell membrane.

Polymorphism. A polymorphism in position 149 is associated with a higher risk of coronary artery disease (CAD). A significantly higher mutation frequency (Arg-149) is observed in patients with angiographically proven severe atherosclerosis compared with an unselected population (Ser-149).

Similarity. Belongs to the selectin/LECAM family.

RefSeq proteins (1): NP_000441* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR000742	EGF	Domain
IPR001304	C-type_lectin-like	Domain
IPR002396	Selectin_superfamily	Family
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR033991	Selectin_CTLD	Domain
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily

Pfam: PF00008, PF00059, PF00084

UniProt features (93 total): strand 25, disulfide bond 19, glycosylation site 11, sequence variant 11, domain 8, binding site 8, helix 3, topological domain 2, turn 2, signal peptide 1, chain 1, transmembrane region 1, mutagenesis site 1

Structure

Experimental structures (PDB)

17 structures.

PDB	Method	Resolution (Å)
1G1T	X-RAY DIFFRACTION	1.5
9RAK	X-RAY DIFFRACTION	1.9
4C16	X-RAY DIFFRACTION	1.93
1ESL	X-RAY DIFFRACTION	2
6EYI	X-RAY DIFFRACTION	2.04
6EYJ	X-RAY DIFFRACTION	2.2
8R5L	X-RAY DIFFRACTION	2.2
9HGW	X-RAY DIFFRACTION	2.2
6EYK	X-RAY DIFFRACTION	2.21
9HGU	X-RAY DIFFRACTION	2.3
9RAL	X-RAY DIFFRACTION	2.4
4CSY	X-RAY DIFFRACTION	2.41
9HGV	X-RAY DIFFRACTION	2.46
8R5M	X-RAY DIFFRACTION	2.49
9HGY	X-RAY DIFFRACTION	2.5
9RAM	X-RAY DIFFRACTION	2.6
9HGX	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16581-F1	83.28	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 101–109; 101; 103; 109; 113–118; 126–128; 126; 127

Disulfide bonds (19): 40–138, 111–130, 143–154, 148–163, 165–174, 180–224, 193–206, 210–237, 242–286, 255–268, 272–299, 304–349, 335–362, 367–412, 398–425, 430–475, 461–488, 493–534, 520–547

Glycosylation sites (11): 25, 145, 160, 179, 199, 203, 265, 312, 332, 503, 527

Mutagenesis-validated functional residues (1):

Position	Phenotype
109	decreased adhesion to cells expressing selplg.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-109582	Hemostasis

MSigDB gene sets: 234 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, MCLACHLAN_DENTAL_CARIES_UP, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, MODULE_418, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, PID_REG_GR_PATHWAY, GOBP_POSITIVE_REGULATION_OF_RECEPTOR_MEDIATED_ENDOCYTOSIS, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT

GO Biological Process (19): positive regulation of receptor internalization (GO:0002092), leukocyte migration involved in inflammatory response (GO:0002523), positive regulation of leukocyte migration (GO:0002687), inflammatory response (GO:0006954), heterophilic cell-cell adhesion (GO:0007157), leukocyte cell-cell adhesion (GO:0007159), phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), calcium-mediated signaling (GO:0019722), actin filament-based process (GO:0030029), response to lipopolysaccharide (GO:0032496), response to cytokine (GO:0034097), response to tumor necrosis factor (GO:0034612), regulation of inflammatory response (GO:0050727), leukocyte tethering or rolling (GO:0050901), response to interleukin-1 (GO:0070555), positive regulation of leukocyte tethering or rolling (GO:1903238), cell adhesion (GO:0007155), leukocyte migration (GO:0050900), obsolete cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742)

GO Molecular Function (7): transmembrane signaling receptor activity (GO:0004888), sialic acid binding (GO:0033691), phospholipase binding (GO:0043274), metal ion binding (GO:0046872), oligosaccharide binding (GO:0070492), protein binding (GO:0005515), carbohydrate binding (GO:0030246)

GO Cellular Component (9): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), caveola (GO:0005901), clathrin-coated pit (GO:0005905), external side of plasma membrane (GO:0009897), cortical cytoskeleton (GO:0030863), membrane raft (GO:0045121), perinuclear region of cytoplasm (GO:0048471), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Hemostasis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inflammatory response	2
leukocyte migration	2
cell-cell adhesion	2
cellular process	2
response to cytokine	2
binding	2
membrane	2
cellular anatomical structure	2
regulation of receptor internalization	1
receptor internalization	1
positive regulation of receptor-mediated endocytosis	1
positive regulation of immune system process	1
regulation of leukocyte migration	1
positive regulation of cell migration	1
defense response	1
G protein-coupled receptor signaling pathway	1
phospholipase C activator activity	1
intracellular signaling cassette	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
response to peptide	1
regulation of defense response	1
regulation of response to external stimulus	1
cellular extravasation	1
leukocyte adhesion to vascular endothelial cell	1
leukocyte tethering or rolling	1
regulation of leukocyte tethering or rolling	1
positive regulation of leukocyte adhesion to vascular endothelial cell	1
immune system process	1
cell migration	1
signaling receptor activity	1
carboxylic acid binding	1
carbohydrate derivative binding	1
enzyme binding	1
cation binding	1
carbohydrate binding	1
cell periphery	1
plasma membrane raft	1
endomembrane system	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

22 interactions, top by confidence:

A	B	Type	Score
CD44	SELE	psi-mi:“MI:0915”(physical association)	0.610
CD44	SELE	psi-mi:“MI:0407”(direct interaction)	0.610
SELE	WFS1	psi-mi:“MI:0915”(physical association)	0.560
SELE	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
SELE	ATXN3	psi-mi:“MI:0915”(physical association)	0.560
SELE	SELPLG	psi-mi:“MI:0407”(direct interaction)	0.440
GLG1	SELE	psi-mi:“MI:0407”(direct interaction)	0.440
SELE	CEACAM1	psi-mi:“MI:0407”(direct interaction)	0.440
SELE	MCAM	psi-mi:“MI:0915”(physical association)	0.400
SELE	CEACAM5	psi-mi:“MI:0915”(physical association)	0.400
SELE	PODXL	psi-mi:“MI:0915”(physical association)	0.400
SELE	SBF1	psi-mi:“MI:0914”(association)	0.350
PTPN11	SELE	psi-mi:“MI:0914”(association)	0.350
TRIM54	SELE	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): PTK2 (Reconstituted Complex), PXN (Reconstituted Complex), ACTA2 (Reconstituted Complex), VCL (Reconstituted Complex), FLNA (Reconstituted Complex), DIP2B (Affinity Capture-MS), DIP2A (Affinity Capture-MS), MBLAC2 (Affinity Capture-MS), MTMR1 (Affinity Capture-MS), SBF1 (Affinity Capture-MS), SELE (Affinity Capture-Western), SELE (Affinity Capture-Western), SELE (Two-hybrid), SELE (Affinity Capture-Western), MTMR1 (Affinity Capture-MS)

ESM2 similar proteins: O08569, O62837, O88174, P02749, P04003, P05160, P08607, P14151, P15529, P16109, P16581, P17690, P19070, P20023, P20851, P26644, P27113, P30836, P33703, P33730, P68638, P68639, P70105, P79138, P98105, P98107, P98131, Q00690, Q01102, Q01339, Q03472, Q07968, Q22328, Q28065, Q28768, Q5R4D0, Q60401, Q60736, Q61475, Q61476

Diamond homologs: A0JNA2, A2AVA0, O02839, O08569, O14594, O19124, O62685, O62837, O88174, P04003, P06681, P08174, P10643, P15529, P16109, P16581, P17927, P19070, P20023, P49457, P55066, P55067, P68638, P68639, P70105, P79138, Q01016, Q03472, Q09101, Q22328, Q28065, Q28085, Q28768, Q29RN8, Q2HRD4, Q2VPA4, Q3SYW2, Q4LDE5, Q4V9Z5, Q501P1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SELE	up-regulates	ITGAL
SELPLG	up-regulates	SELE	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 13 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cell surface interactions at the vascular wall	5	43.3×	6e-06

GO biological processes:

GO term	Partners	Fold	FDR
cell adhesion	5	14.4×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	6
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

1275 predictions. Top by Δscore:

Variant	Effect	Δscore
1:169725799:CTG:C	acceptor_gain	1.0000
1:169725802:C:CC	acceptor_gain	1.0000
1:169725924:CTTTG:C	acceptor_gain	1.0000
1:169725925:TTTG:T	acceptor_gain	1.0000
1:169725926:TTG:T	acceptor_gain	1.0000
1:169725927:TG:T	acceptor_gain	1.0000
1:169725927:TGCTG:T	acceptor_loss	1.0000
1:169725929:C:CC	acceptor_gain	1.0000
1:169725929:CT:C	acceptor_loss	1.0000
1:169726692:T:TA	donor_gain	1.0000
1:169726694:CTCA:C	donor_loss	1.0000
1:169726695:TCA:T	donor_loss	1.0000
1:169726696:CA:C	donor_loss	1.0000
1:169726697:A:T	donor_loss	1.0000
1:169726698:C:CT	donor_loss	1.0000
1:169726804:GAG:G	acceptor_gain	1.0000
1:169726806:GC:G	acceptor_loss	1.0000
1:169726807:C:CC	acceptor_gain	1.0000
1:169726807:C:CG	acceptor_loss	1.0000
1:169727347:A:C	donor_loss	1.0000
1:169727348:C:CA	donor_loss	1.0000
1:169727526:C:CC	acceptor_gain	1.0000
1:169729181:CTTA:C	donor_loss	1.0000
1:169729182:TTACC:T	donor_loss	1.0000
1:169729183:TACCT:T	donor_loss	1.0000
1:169729184:A:AC	donor_gain	1.0000
1:169729185:C:CC	donor_gain	1.0000
1:169729370:CACAG:C	acceptor_gain	1.0000
1:169729371:ACAG:A	acceptor_gain	1.0000
1:169729372:CAG:C	acceptor_gain	1.0000

AlphaMissense

4022 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:169732661:C:A	W125C	0.998
1:169732661:C:G	W125C	0.998
1:169732663:A:G	W125R	0.997
1:169732663:A:T	W125R	0.997
1:169732745:C:A	W97C	0.997
1:169732745:C:G	W97C	0.997
1:169732623:C:G	C138S	0.996
1:169732624:A:T	C138S	0.996
1:169732823:C:A	W71C	0.995
1:169732823:C:G	W71C	0.995
1:169732704:C:G	C111S	0.994
1:169732705:A:T	C111S	0.994
1:169732917:C:G	C40S	0.994
1:169732918:A:T	C40S	0.994
1:169732793:C:A	W81C	0.993
1:169732793:C:G	W81C	0.993
1:169732916:A:C	C40W	0.993
1:169732622:G:C	C138W	0.992
1:169732624:A:G	C138R	0.992
1:169732705:A:G	C111R	0.992
1:169731903:C:G	C154S	0.991
1:169731904:A:T	C154S	0.991
1:169732647:C:G	C130S	0.991
1:169732648:A:T	C130S	0.991
1:169728083:C:A	W418C	0.990
1:169728083:C:G	W418C	0.990
1:169732747:A:G	W97R	0.990
1:169732747:A:T	W97R	0.990
1:169732860:A:G	L59P	0.990
1:169729211:C:A	W355C	0.989

dbSNP variants (sampled 300 via entrez): RS1000173481 (1:169727068 C>T), RS1000690421 (1:169731381 G>A,T), RS1000718380 (1:169724042 A>C), RS1000725733 (1:169731078 G>C), RS1000749586 (1:169724407 A>G), RS1001391451 (1:169727315 A>G,T), RS1001750675 (1:169727741 T>C), RS1001877461 (1:169732327 A>G), RS1001951376 (1:169733616 T>C,G), RS1002130743 (1:169733939 G>A), RS1002183292 (1:169735068 G>A), RS1002630891 (1:169728961 T>A), RS1002637015 (1:169722627 C>G), RS1002739939 (1:169735282 CT>C,CTTTTT), RS1002748426 (1:169729176 T>C)

Disease associations

OMIM: gene MIM:131210 | disease phenotypes: MIM:161950

GenCC curated gene-disease

Mondo (2): IgA nephropathy, susceptibility to (MONDO:0100555), coronary artery disorder (MONDO:0005010)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003043_84	Inflammatory bowel disease	3.000000e-08
GCST006585_2667	Blood protein levels	8.000000e-07
GCST90002393_165	Monocyte count	5.000000e-12
GCST90002394_90	Monocyte percentage of white cells	4.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005091	monocyte count
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003324	Coronary Artery Disease	C14.280.647.250.260; C14.907.137.126.339; C14.907.585.250.260

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3831288 (PROTEIN FAMILY), CHEMBL3890 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 145 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3707446	RIVIPANSEL	3	145

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3917412	Efficacy	3	capecitabine;fluorouracil;leucovorin;oxaliplatin	Colonic Neoplasms

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3917412	SELE	3	2.25	1	capecitabine;fluorouracil;leucovorin;oxaliplatin

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
uproleselan	Antagonist	5.76	pIC50

ChEMBL bioactivities

171 potent at pChembl≥5 of 216 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.15	IC50	0.7	nM	CHEMBL119501
9.00	IC50	1	nM	CHEMBL119733
8.70	IC50	2	nM	CHEMBL118113
8.70	IC50	2	nM	CHEMBL325184
8.55	IC50	2.8	nM	CHEMBL119335
8.52	IC50	3	nM	CHEMBL117198
8.40	IC50	4	nM	CHEMBL117279
8.40	IC50	4	nM	CHEMBL119039
8.40	IC50	4	nM	CHEMBL116070
8.30	IC50	5	nM	CHEMBL266198
8.30	IC50	5	nM	CHEMBL117894
8.30	IC50	5	nM	CHEMBL117746
8.30	IC50	5	nM	CHEMBL118034
8.30	IC50	5	nM	CHEMBL117668
8.30	IC50	5	nM	CHEMBL117279
8.22	IC50	6	nM	CHEMBL326120
8.22	IC50	6	nM	CHEMBL117279
8.22	IC50	6	nM	CHEMBL118518
8.22	IC50	6	nM	CHEMBL116070
8.22	IC50	6	nM	CHEMBL116152
8.15	IC50	7	nM	CHEMBL326271
8.15	IC50	7	nM	CHEMBL331584
8.10	IC50	8	nM	CHEMBL118074
8.10	IC50	8	nM	CHEMBL118886
8.05	IC50	9	nM	CHEMBL115637
7.92	IC50	12	nM	CHEMBL268567
7.89	IC50	13	nM	CHEMBL267125
7.89	IC50	13	nM	CHEMBL116363
7.89	IC50	13	nM	CHEMBL326771
7.80	IC50	16	nM	CHEMBL119183
7.75	IC50	18	nM	CHEMBL115971
7.72	IC50	19	nM	CHEMBL116089
7.70	IC50	20	nM	CHEMBL267678
7.70	IC50	20	nM	CHEMBL118074
7.70	IC50	20	nM	CHEMBL117453
7.70	IC50	20	nM	CHEMBL116307
7.70	IC50	20	nM	CHEMBL267456
7.68	IC50	21	nM	CHEMBL118299
7.60	IC50	25	nM	CHEMBL115966
7.60	IC50	25	nM	CHEMBL118074
7.60	IC50	25	nM	CHEMBL419046
7.55	IC50	28	nM	CHEMBL116454
7.55	IC50	28	nM	CHEMBL118022
7.52	IC50	30	nM	CHEMBL119732
7.51	IC50	31	nM	CHEMBL118089
7.51	IC50	31	nM	CHEMBL119091
7.50	IC50	32	nM	CHEMBL269598
7.47	IC50	34	nM	CHEMBL325651
7.46	IC50	35	nM	CHEMBL117093
7.46	IC50	35	nM	CHEMBL117936

PubChem BioAssay actives

150 with measured affinity, of 586 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0007	uM
4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0010	uM
4-[4-(oxan-2-yloxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0020	uM
4-(4-imidazol-1-ylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0020	uM
4-[4-[3-hydroxy-3-[4-[2-(methylcarbamoyl)thieno[2,3-c]pyridin-4-yl]oxyphenyl]butanoyl]phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0028	uM
4-(4-cyanophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0030	uM
N-methyl-4-(4-pyrazol-1-ylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0040	uM
4-[4-[2-(2-methoxyethoxy)ethoxymethyl]phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202426: In vitro inhibitory potency compared to TNF-alpha induced Selectin E in human endothelial cells (ELISA assay)	ic50	0.0040	uM
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0040	uM
4-[4-(furan-2-yl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0050	uM
N-methyl-4-(4-thiophen-2-ylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0050	uM
4-[4-(2-methoxyethoxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0050	uM
4-[4-[2-(2-methoxyethoxy)ethoxymethyl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0050	uM
4-(4-bromophenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0050	uM
4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0060	uM
4-(4-imidazol-1-ylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0060	uM
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0060	uM
4-(4-bromophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0070	uM
4-[4-(2-methoxyethoxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0070	uM
4-(4-chloro-3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0080	uM
4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0080	uM
N-methyl-4-(4-phenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0090	uM
4-(4-chlorophenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0120	uM
4-(3,4-dimethylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0130	uM
4-[4-(methoxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0130	uM
4-[4-[(E)-N’-hydroxycarbamimidoyl]phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0130	uM
4-[4-(methoxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0160	uM
4-(4-cyanophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0180	uM
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0190	uM
ethyl 4-(2-carbamoylthieno[2,3-c]pyridin-4-yl)oxybenzoate	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0200	uM
4-(4-methylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0200	uM
4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0200	uM
4-phenylsulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0200	uM
4-(4-acetylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0210	uM
4-[4-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0250	uM
4-[4-(hydroxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0250	uM
4-[4-(hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0280	uM
N-methyl-4-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0280	uM
4-(4-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0300	uM
4-[4-[1-(hydroxymethyl)cyclopropyl]phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0310	uM
4-(4-chlorophenoxy)-N-ethylthieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0310	uM
4-(4-methylphenyl)sulfanylthieno[2,3-c]pyridine-2-carbohydrazide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0320	uM
4-[4-[(E)-3-(2-morpholin-4-ylethylamino)-3-oxoprop-1-enyl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0340	uM
4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0350	uM
N-methyl-4-(4-morpholin-4-ylphenoxy)thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0350	uM
N-methyl-4-[4-[(E)-3-(2-morpholin-4-ylethylamino)-3-oxoprop-1-enyl]phenoxy]thieno[2,3-c]pyridine-2-carboxamide	202422: Inhibition of selectin E in human endothelial cells	ic50	0.0430	uM
4-(2,4-dimethylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0430	uM
4-[4-(trifluoromethyl)phenyl]sulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0440	uM
4-(3-methylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0450	uM
5-methoxy-3-propan-2-yloxy-1-benzothiophene-2-carboxamide	202427: In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay	ic50	0.0500	uM

CTD chemical–gene interactions

182 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
lipopolysaccharide, Escherichia coli O111 B4	increases expression, affects cotreatment, affects reaction, decreases reaction	6
Glucose	decreases reaction, increases expression, increases secretion, affects reaction	6
Lipopolysaccharides	increases reaction, decreases reaction, affects reaction, affects cotreatment, increases expression	6
Quercetin	affects cotreatment, decreases reaction, increases expression	5
Simvastatin	decreases expression, decreases reaction, increases expression, increases reaction, affects expression	4
Particulate Matter	decreases reaction, increases expression, affects expression, increases reaction, increases abundance	4
titanium dioxide	decreases reaction, increases expression	3
Resveratrol	increases expression, decreases expression, affects reaction, decreases reaction	3
Benzo(a)pyrene	decreases expression, increases expression, increases methylation, affects methylation	3
Smoke	increases expression, decreases reaction, decreases nitrosation, affects reaction	3
kaempferol	affects cotreatment, decreases reaction, increases expression	2
cyanidin-3-O-beta-glucopyranoside	increases expression, decreases reaction	2
aspalathin	decreases reaction, increases expression	2
nothofagin	decreases reaction, increases expression	2
dabrafenib	decreases reaction, increases expression	2
Lycopene	affects cotreatment, decreases reaction, increases expression	2
Acetylcysteine	decreases reaction, increases expression, decreases expression	2
Vehicle Emissions	affects expression, increases abundance, increases expression	2
Curcumin	decreases reaction, increases expression, affects expression	2
Hydrogen Peroxide	increases secretion, increases expression, decreases reaction	2
Polyphosphates	decreases reaction, increases expression	2
Silicon Dioxide	decreases reaction, increases expression	2
Triterpenes	increases expression, decreases reaction	2
Sertraline	decreases expression	2
alpha-Tocopherol	decreases reaction, increases expression, affects cotreatment	2
Apigenin	increases expression, decreases reaction	2
tetrachlorobenzoquinone	increases reaction, decreases reaction, increases expression	1
peracetylated N-azidoacetylmannosamine	decreases expression	1
parthenolide	decreases expression	1
neocuproine	affects abundance, decreases reaction, increases expression	1

ChEMBL screening assays

118 unique, capped per target: 108 binding, 10 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1071032	Binding	Ratio of compound IC50 to sialyl Lewis X IC50 for E-selectin by ELISA	Probing the carbohydrate recognition domain of E-selectin: the importance of the acid orientation in sLex mimetics. — Bioorg Med Chem
CHEMBL3214900	Functional	PubChem BioAssay. Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_Dose_CherryPick_Activity. (absACnn = the concentration at which the curve crosses t	PubChem BioAssay data set

Cellosaurus cell lines

2 cell lines: 1 spontaneously immortalized cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1BC	CHO Pro-5-Esel	Spontaneously immortalized cell line	Female
CVCL_E4JI	L1-2/pMRB107	Cancer cell line

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00025766	PHASE4	COMPLETED	Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack
NCT00079638	PHASE4	COMPLETED	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00111566	PHASE4	COMPLETED	BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention
NCT00129038	PHASE4	COMPLETED	Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
NCT00133003	PHASE4	COMPLETED	Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
NCT00133237	PHASE4	COMPLETED	Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
NCT00133692	PHASE4	COMPLETED	INVEST: INternational VErapamil SR Trandolapril STudy
NCT00139386	PHASE4	COMPLETED	Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
NCT00140465	PHASE4	COMPLETED	75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
NCT00140530	PHASE4	COMPLETED	Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)
NCT00146575	PHASE4	COMPLETED	Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)
NCT00152308	PHASE4	TERMINATED	Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis
NCT00155350	PHASE4	UNKNOWN	Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
NCT00162370	PHASE4	COMPLETED	A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
NCT00163202	PHASE4	COMPLETED	Comparative Atorvastatin Pleiotropic Effects
NCT00169819	PHASE4	COMPLETED	EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study
NCT00171275	PHASE4	COMPLETED	Fluvastatin in the Therapy of Acute Coronary Syndrome
NCT00175240	PHASE4	COMPLETED	Enhancing the Secondary Prevention of Coronary Artery Disease
NCT00180388	PHASE4	TERMINATED	VENEK: Healing in Different Vein Harvesting Methods During Aortocoronary Coronary Artery Bypass Graft Surgery (CABG)
NCT00180583	PHASE4	COMPLETED	Vision II: Evaluation of GALILEO Intravascular Radiotherapy System
NCT00189215	PHASE4	COMPLETED	Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?
NCT00200629	PHASE4	TERMINATED	Both Exercise and Adenosine Stress Testing
NCT00202904	PHASE4	COMPLETED	Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
NCT00209404	PHASE4	COMPLETED	Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)
NCT00209430	PHASE4	COMPLETED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
NCT00220558	PHASE4	UNKNOWN	GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions
NCT00222261	PHASE4	COMPLETED	Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
NCT00229528	PHASE4	COMPLETED	Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease
NCT00232804	PHASE4	COMPLETED	The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent
NCT00232856	PHASE4	COMPLETED	A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.
NCT00235066	PHASE4	COMPLETED	The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
NCT00235092	PHASE4	COMPLETED	The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus
NCT00235950	PHASE4	COMPLETED	Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
NCT00238004	PHASE4	UNKNOWN	The Low HDL On Six Weeks Statin Therapy (LOW) Study
NCT00241904	PHASE4	COMPLETED	Reducing Total Cardiovascular Risk in an Urban Community
NCT00242944	PHASE4	COMPLETED	Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)
NCT00243477	PHASE4	COMPLETED	MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting
NCT00244530	PHASE4	COMPLETED	Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery
NCT00245401	PHASE4	COMPLETED	CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)